Veterinary Oncology Market Size & Growth Forecast 2027–2036, By Segments (Cancer Diagnostics & Treatment, Cancer Type, Animal Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Veterinary Oncology Market size was valued at USD 2.13 Billion in 2026 and is projected to grow at 10.71% CAGR from 2027 to 2036, surpassing USD 5.89 Billion by 2036. The industry revenue for 2027 is estimated at USD 2.33 Billion.
Base Year Value (2026)
USD 2.13 Billion
CAGR (2027-2036)
10.71%
Forecast Year Value (2036)
USD 5.89 Billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036
Veterinary Oncology Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America held 46% in 2026, supported by advanced veterinary care infrastructure, greater awareness, specialized treatment adoption, and improved diagnostic and therapeutic capabilities.
- Asia Pacific is the fastest-growing region, driven by rising pet ownership, improving veterinary infrastructure, urbanization, and expanding access to specialized cancer diagnosis and treatment.
-
Segment Momentum:
- The treatment segment led the veterinary oncology market with a 59.57% share in 2026 and was also the fastest-growing segment, driven by rising cancer diagnoses, advanced therapies, and greater adoption of specialized veterinary oncology services.
- The lymphomas segment accounted for 31% of the market in 2026 while also recording the fastest growth, supported by frequent diagnoses, earlier detection, improved treatment protocols, and continued research into innovative therapies.
-
Market Expansion Drivers:
- Rising pet cancer incidence driving increased demand for advanced veterinary oncology treatments
- Advancements in veterinary cancer diagnostics enabling earlier and more precise treatment
- Growing investment in pet healthcare research accelerating oncology drug development pipelines
-
Leading Market Participants:
Top players in the veterinary oncology market include Zoetis Inc. (United States), Elanco Animal Health Incorporated (United States), Boehringer Ingelheim International GmbH (Germany), Virbac S.A. (France), AB Science S.A. (France), Varian Medical Systems, Inc. (United States), Accuray Incorporated (United States), Karyopharm Therapeutics Inc. (United States), PetCure Oncology (United States), Nippon Zenyaku Kogyo Co., Ltd. (Japan)
Global Market Forecast Snapshot:
-
Market Outlook:
- 2026 Market Size: USD 2.13 Billion
- 2027 Estimated Market Size: USD 2.33 Billion
- Projected Market Size: USD 5.89 Billion by 2036
- Growth Forecasts: 10.71% CAGR (2027-2036)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Treatment (Cancer Diagnostics & Treatment) | Lymphomas (Cancer Type) | Canine (Animal Type)
- Emerging Opportunity Segment: Treatment (Cancer Diagnostics & Treatment) | Lymphomas (Cancer Type) | Canine (Animal Type)
Market Growth Drivers and Industry Trends
Rising pet cancer incidence driving increased demand for advanced veterinary oncology treatments
An increasing number of companion animals are being diagnosed with various forms of cancer as pet lifespans extend and awareness of animal health improves among owners. The veterinary oncology market growth is driven by growing demand for specialized treatment options that address complex oncological conditions through advanced therapeutic approaches and comprehensive clinical care. Veterinary practices are expanding oncology services while pet owners increasingly seek interventions that improve treatment outcomes and quality of life for affected animals.
Advancements in veterinary cancer diagnostics enabling earlier and more precise treatment
Continuous improvements in diagnostic technologies are allowing veterinarians to identify cancer at earlier stages and develop more targeted treatment strategies based on accurate clinical assessments. These innovations will propel the veterinary oncology market growth by supporting timely disease detection, improved tumor characterization, and more informed therapeutic planning. Enhanced diagnostic capabilities also facilitate ongoing monitoring of treatment response, enabling clinicians to refine care protocols according to individual patient needs throughout the course of therapy.
Growing investment in pet healthcare research accelerating oncology drug development pipelines
Rising research activity in companion animal medicine is expanding the development of innovative therapies designed specifically for veterinary oncology applications. As investment increases across drug discovery, clinical evaluation, and translational research, the veterinary oncology market benefits from a broader pipeline of treatment candidates addressing different cancer types in animals. Collaborative research efforts also improve scientific understanding of disease mechanisms, supporting the development of more targeted therapeutic approaches and specialized veterinary treatment options.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising pet cancer incidence driving increased demand for advanced veterinary oncology treatments | 2% | High | North America, Europe | High | Near Term |
| Advancements in veterinary cancer diagnostics enabling earlier and more precise treatment | 1.7% | High | Asia Pacific, North America | High | Mid Term |
| Growing investment in pet healthcare research accelerating oncology drug development pipelines | 1.5% | Moderate | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
46% Market Share in 2026
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)
North America held the largest share of the veterinary oncology market, accounting for 46% in 2026, supported by increasing awareness of companion animal healthcare, greater adoption of advanced veterinary diagnostic and treatment approaches, and the presence of well-developed veterinary care infrastructure. Rising pet ownership and growing willingness among owners to pursue specialized treatment for cancer are strengthening demand for veterinary oncology services. In addition, improvements in veterinary imaging, pathology, surgical procedures, and therapeutic options are supporting earlier disease identification and more comprehensive cancer management across the region.
Asia Pacific is expected to experience the fastest growth, driven by rising companion animal ownership, improving veterinary healthcare infrastructure, and increasing awareness of animal health and preventive care. Growing urbanization and changing household attitudes toward pets are encouraging greater spending on advanced veterinary services, including cancer diagnosis and treatment. The gradual expansion of specialized veterinary facilities and increasing access to modern diagnostic technologies are also creating favorable conditions for broader adoption of oncology-focused veterinary care.
Key Country Insights
The U.S. veterinary oncology market is shaped by expanding access to specialty veterinary hospitals, advanced diagnostics, and cancer therapeutics for companion animals. Commercial activity increasingly centers on precision treatment options, clinical collaborations, and wider adoption of referral-based oncology services.
Japan continues to strengthen veterinary oncology through increasing demand for specialized cancer care driven by an aging companion animal population. Veterinary clinics are expanding access to minimally invasive treatments and advanced therapeutic technologies suited to long-term patient management.
South Korea is expanding veterinary oncology capabilities through investments in modern animal hospitals and advanced treatment technologies. Growing interest in companion animal healthcare supports broader adoption of oncology diagnostics, immunotherapies, and specialized veterinary services.
Germany emphasizes integrating advanced imaging, pathology, and oncology services within veterinary practice. The country's focus on evidence-based treatment protocols supports demand for innovative cancer diagnostics and targeted therapies for companion animals.
France is reinforcing veterinary oncology through stronger referral networks connecting primary veterinarians with specialized oncology centers. The market increasingly prioritizes comprehensive cancer diagnosis, multimodal treatment planning, and supportive care for companion animals.
Italy is expanding access to veterinary oncology by strengthening specialist clinics and advanced diagnostic capabilities. The country's market increasingly supports integrated cancer care combining surgery, chemotherapy, and imaging within dedicated veterinary healthcare facilities.
Segment Leadership and Growth Trends
Cancer Diagnostics & Treatment Segment Analysis: Treatment (Largest & Fastest-Growing Segment)
The veterinary oncology market was led by the treatment segment, which held a 59.57% share in 2026 while also representing the fastest-growing segment. The increasing diagnosis of cancer in companion animals, coupled with greater willingness among pet owners to pursue advanced therapeutic options, continues to drive demand for veterinary cancer treatments. Expanding availability of targeted therapies, immunotherapies, chemotherapy protocols, and multimodal treatment approaches has improved clinical outcomes, encouraging broader adoption across veterinary practices. Rising investments in specialized veterinary oncology services and increasing awareness of early intervention further reinforce the segment's dominant position.
Cancer Type Segment Analysis: Lymphomas (Largest & Fastest-Growing Segment)
Within the veterinary oncology market, the lymphomas segment accounted for the largest share of 31% in 2026 and also emerged as the fastest-growing segment. Lymphoma remains one of the most frequently diagnosed cancers in companion animals, resulting in consistent demand for diagnostic evaluations and long-term treatment strategies. Improved awareness among veterinarians and pet owners, combined with advancements in diagnostic imaging, pathology, and therapeutic protocols, supports earlier diagnosis and more effective disease management. Continued research into innovative treatment approaches is expected to further strengthen the segment's growth.
Animal Type Segment Analysis: Canine (Largest & Fastest-Growing Segment)
Holding the largest share of the veterinary oncology market, the canine segment maintained its dominant position in 2026 while also recording the fastest growth. Dogs represent the largest patient population for veterinary oncology services due to their higher incidence of various cancers and increasing access to specialized veterinary care. Growing pet ownership, rising expenditure on companion animal health, and improved availability of advanced cancer diagnostics and treatment options continue to support demand within the canine segment. Increased emphasis on extending pet lifespan and improving quality of life is also contributing to sustained segment expansion.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Cancer Diagnostics & Treatment | Diagnostics, Treatment | Treatment | Treatment |
| Cancer Type | Mast Cell Tumors, Mammary Tumors, Lymphomas, Melanoma, Others | Lymphomas | Lymphomas |
| Animal Type | Canine, Feline, Equine, Others | Canine | Canine |
Read our Research ApproachCompetitive Landscape and Market Positioning
Major players in the veterinary oncology market:
- Zoetis, Inc. (United States)
- Elanco Animal Health Incorporated (United States)
- Boehringer Ingelheim International GmbH (Germany)
- Virbac S.A. (France)
- AB Science S.A. (France)
- Varian Medical Systems, Inc. (United States)
- Accuray Incorporated (United States)
- Karyopharm Therapeutics, Inc. (United States)
- PetCure Oncology (United States)
- Nippon Zenyaku Kogyo Co., Ltd. (Japan)
Advances in companion animal healthcare are encouraging a more specialized competitive environment, where providers compete through broader treatment capabilities and improved clinical precision rather than conventional therapeutic offerings alone. Increasing emphasis on earlier diagnosis, personalized treatment planning, and minimally invasive interventions is driving investment in integrated oncology services that combine diagnostics, therapeutics, and long-term patient management. As pet owners place greater value on quality-of-life outcomes, market participants are also expanding supportive care, follow-up monitoring, and multidisciplinary treatment approaches that strengthen differentiation in an increasingly specialized clinical landscape.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Zoetis Inc. | Apr-25 | Zoetis expanded its companion animal oncology pipeline, advancing multiple candidates for canine lymphoma and osteosarcoma into clinical validation studies. The initiative utilizes partnerships with academic veterinary institutions to strengthen the company’s competitive position in specialized cancer therapeutics and drug development. |
| PetCure Oncology | Feb-25 | PetCure Oncology expanded its national treatment network by opening a new stereotactic radiosurgery facility in the southeastern United States. This infrastructure investment enhances regional access to advanced oncology services, reducing reliance on long-distance referrals and increasing the company's operational footprint in the veterinary radiation oncology sector. |
| IDEXX Laboratories | Jan-25 | IDEXX Laboratories enhanced its oncology diagnostic capabilities through the launch of an updated pathology panel via its VetPath service. The platform integrates advanced biomarker profiling for canine lymphoma subtyping and treatment response monitoring, representing a strategic focus on diagnostic innovation within the veterinary oncology value chain. |
| Accuray Incorporated | Sep-24 | Accuray completed the installation of CyberKnife robotic radiosurgery systems at two North American university veterinary hospitals. This expansion strengthens the company's footprint in the academic veterinary market and increases the availability of precision radiotherapy technology for companion animal cancer care. |
| Dechra Pharmaceuticals PLC | Jul-24 | Dechra Pharmaceuticals announced a strategic initiative to enter the veterinary oncology supportive care segment. The company plans to leverage both organic development and in-licensing opportunities to build a portfolio in this category, following the successful integration of its recent business acquisitions. |
| Iowa State University | Jun-24 | Iowa State University announced a $7.5 million expansion of the Lloyd Veterinary Medical Center to include the new ISU Pet Cancer Clinic. Scheduled for construction in early 2026, the facility is designed to enhance clinical capacity, research output, and specialized oncology education across the Midwest region. |
| Merck Animal Health | Feb-24 | Merck Animal Health entered a research collaboration with a North American university to advance the development of cancer vaccines for companion animals. The partnership focuses on early-stage clinical research, specifically targeting canine melanoma to expand the company’s therapeutic pipeline in veterinary oncology. |
| Elanco Animal Health Incorporated | Jun-23 | Elanco completed a strategic licensing agreement for a novel immunomodulatory compound intended for use as a companion animal oncology supportive therapy. This investment indicates a strategic shift to diversify the company's oncology pipeline beyond conventional pharmaceutical products into advanced immunotherapies. |
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
